| Jun 14 |
Capricor Therapeutics files for $150M mixed shelf
|
| Jun 11 |
Sector Update: Health Care Stocks Decline Tuesday Afternoon
|
| Jun 11 |
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
|
| Jun 10 |
Capricor Advances in DMD Therapy With Positive Study Data
|
| Jun 10 |
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data
|
| Jun 4 |
What's Going On With Capricor Therapeutics Stock Tuesday?
|
| Jun 4 |
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
|
